IL283884A - Antibodies against il-36 and methods of using them - Google Patents

Antibodies against il-36 and methods of using them

Info

Publication number
IL283884A
IL283884A IL283884A IL28388421A IL283884A IL 283884 A IL283884 A IL 283884A IL 283884 A IL283884 A IL 283884A IL 28388421 A IL28388421 A IL 28388421A IL 283884 A IL283884 A IL 283884A
Authority
IL
Israel
Prior art keywords
antibodies
methods
Prior art date
Application number
IL283884A
Other languages
English (en)
Hebrew (he)
Inventor
& Luzzatto Luzzatto
Original Assignee
23Andme Inc
& Luzzatto Luzzatto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 23Andme Inc, & Luzzatto Luzzatto filed Critical 23Andme Inc
Publication of IL283884A publication Critical patent/IL283884A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL283884A 2018-12-21 2021-06-10 Antibodies against il-36 and methods of using them IL283884A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862784316P 2018-12-21 2018-12-21
PCT/US2019/067435 WO2020132220A1 (en) 2018-12-21 2019-12-19 Anti-il-36 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
IL283884A true IL283884A (en) 2021-07-29

Family

ID=69187940

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283884A IL283884A (en) 2018-12-21 2021-06-10 Antibodies against il-36 and methods of using them

Country Status (20)

Country Link
US (2) US11884719B2 (https=)
EP (1) EP3898673A1 (https=)
JP (1) JP2022514950A (https=)
KR (1) KR20210107721A (https=)
CN (1) CN113454113A (https=)
AR (1) AR123405A1 (https=)
AU (1) AU2019405782A1 (https=)
BR (1) BR112021010374A2 (https=)
CA (1) CA3120474A1 (https=)
CL (1) CL2021001615A1 (https=)
CO (1) CO2021007882A2 (https=)
EA (1) EA202191656A1 (https=)
IL (1) IL283884A (https=)
MX (1) MX2021007589A (https=)
PE (1) PE20211295A1 (https=)
PH (1) PH12021551422A1 (https=)
SG (1) SG11202106100VA (https=)
TW (1) TW202035460A (https=)
WO (1) WO2020132220A1 (https=)
ZA (1) ZA202103311B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925932A (zh) 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
WO2021259880A1 (en) * 2020-06-22 2021-12-30 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
BR112022026999A2 (pt) * 2020-07-17 2023-01-24 Boehringer Ingelheim Int Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022150644A1 (en) * 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022150642A1 (en) * 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
BR9606706A (pt) * 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
US5863769A (en) 1997-01-28 1999-01-26 Smithkline Beecham Corporation DNA encoding interleukin-1 receptor antagonist (IL-1raβ)
US6054559A (en) 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
CA2317918A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Il-1 delta dna and polypeptides
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030092063A1 (en) 1998-05-15 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE69932247T2 (de) 1998-08-21 2007-05-31 Immunex Corp., Thousand Oaks Menschliches il-1 epsilon dna und polypeptide
US6838290B2 (en) 1998-08-21 2005-01-04 Immunex Corporation Methods for screening compounds that affect IL-1 epsilon activity
US6680380B1 (en) 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
EP1141299A2 (en) 1998-12-23 2001-10-10 Genentech, Inc. Il-1 related polypeptides
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US20020068279A1 (en) 1999-12-06 2002-06-06 Curagen Corporation Novel Proteins and nucleic acids encoding the same
WO2001041792A1 (en) 1999-12-10 2001-06-14 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US6843987B2 (en) 2000-02-02 2005-01-18 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030166069A1 (en) 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20030224984A1 (en) 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003034984A2 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003230775A1 (en) 2002-04-01 2003-10-20 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
CA2499843A1 (en) 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2008033333A2 (en) * 2006-09-08 2008-03-20 Amgen Inc. Il-1 family variants
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
JP5511654B2 (ja) 2007-05-31 2014-06-04 ゲンマブ エー／エス 分子操作により得られた組換え非グリコシル化一価半抗体
US20100255012A1 (en) 2007-05-31 2010-10-07 Genmab A/S Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
EP2593595B1 (en) 2010-07-16 2020-03-11 Avantgen, Inc. Novel peptides and uses thereof
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130102486A1 (en) 2011-10-20 2013-04-25 The Board Of Trustees Of The Leland Stanford Junior University Perp as a prognostic and diagnostic marker for dysplasia and cancer
SI3536710T1 (sl) * 2011-11-16 2026-04-30 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
WO2015086830A1 (en) 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
EP3132053B1 (en) 2014-04-15 2020-09-30 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Differential diagnosis of eczema and psoriasis
EP3193906B1 (en) 2014-09-18 2020-11-11 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin Use of peptide inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
US10526404B2 (en) * 2015-04-29 2020-01-07 Institute For Research In Biomedicine Multispecific anti GM-CSF antibodies
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
RU2021120719A (ru) * 2015-09-30 2021-11-03 Медиммьюн Лимитед Композиции и способы подавления раковых стволовых клеток
EA201891084A1 (ru) * 2015-11-02 2019-10-31 Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
CN110035771B (zh) * 2016-10-21 2024-03-08 阿迪马布有限责任公司 抗呼吸道合胞病毒抗体及其产生和使用方法
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
EP3401332A1 (en) * 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions

Also Published As

Publication number Publication date
BR112021010374A2 (pt) 2021-08-24
EP3898673A1 (en) 2021-10-27
US20240132582A1 (en) 2024-04-25
MX2021007589A (es) 2021-12-10
PE20211295A1 (es) 2021-07-20
US11884719B2 (en) 2024-01-30
CA3120474A1 (en) 2020-06-25
KR20210107721A (ko) 2021-09-01
JP2022514950A (ja) 2022-02-16
CL2021001615A1 (es) 2021-11-26
ZA202103311B (en) 2022-10-26
TW202035460A (zh) 2020-10-01
EA202191656A1 (ru) 2021-10-26
AR123405A1 (es) 2022-11-30
SG11202106100VA (en) 2021-07-29
CO2021007882A2 (es) 2021-06-21
CN113454113A (zh) 2021-09-28
PH12021551422A1 (en) 2022-05-02
WO2020132220A9 (en) 2020-09-10
AU2019405782A1 (en) 2021-06-17
WO2020132220A1 (en) 2020-06-25
US20200199217A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
IL276731A (en) Antibodies against CD73 and methods of using them
IL278821A (en) Anti-SIRPA antibodies and methods of using them
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
ZA202300348B (en) Anti-sortilin antibodies and methods of use thereof
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
SI3618863T1 (sl) Protitelesa proti tigitu in načini uporabe njih
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
SG11202106498XA (en) Anti-ctla4 antibodies and methods of use thereof
ES3064823T3 (en) Anti-ly6g6d antibodies and methods of use
IL269077A (en) Anti-gitr antibodies and methods of use thereof
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
IL287282A (en) Anti-mertk antibodies and methods of using them
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
IL290741A (en) Antibodies against cd-96 and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL273538A (en) Anti-TRKB Monoclonal Antibodies and Methods of Use
IL279227A (en) Anti-SIGLEC-7 antibodies and methods of using them
IL268568A (en) TRAILshort antibody and methods of use
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL288886A (en) Antibodies and methods of use
ZA202002144B (en) Antibodies and methods of use